Stay updated on Tislelizumab & Sitravatinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tislelizumab & Sitravatinib in NSCLC Clinical Trial page.

Latest updates to the Tislelizumab & Sitravatinib in NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe update shows a small revision-history change, with Revision: v3.3.4 being added and Revision: v3.3.3 removed from the log. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedRevision: v3.3.3 was added to the page history and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed; these changes appear to be system/versioning and footer-level updates rather than alterations to study data or core page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check55 days agoChange DetectedA new revision entry 'Revision: v3.3.2' was added to the Record History, and the older 'Revision: v3.2.0' entry was removed.SummaryDifference0.1%

- Check62 days agoChange DetectedThe government funding lapse notice banner on the page was removed. The rest of the record history and trial details appear unchanged.SummaryDifference0.6%

- Check76 days agoChange DetectedVersion 18 (2025-06-11) adds updates to Study Identification, Study Status, Study Description, Arms and Interventions, and Outcome Measures. This reflects revised or newly reported trial details and status.SummaryDifference0.2%

- Check105 days agoChange DetectedKey updates: add an important operating-status notice and a new version tag (v3.2.0); remove the old version tag (v3.1.0).SummaryDifference11%

Stay in the know with updates to Tislelizumab & Sitravatinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tislelizumab & Sitravatinib in NSCLC Clinical Trial page.